For the year ending 2025-12-31, CATX had -$30,951K decrease in cash & cash equivalents over the period. -$95,233K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -103,121 |
| Foreign currency adjustments | -250 |
| Depreciation expense and amortization | 3,251 |
| Loss on disposal of property and equipment | 0 |
| Net accretion of discounts on available-for-sale securities | -2,723 |
| Loss on divestiture | 0 |
| Goodwill impairment | 0 |
| In-process research and development impairment | 10,000 |
| Share-based compensation | 8,966 |
| Deferred income tax benefit | -793 |
| Other, net | -5 |
| Accounts receivable | -110 |
| Inventory related to discontinued operations (note 4) | 0 |
| Interest receivable | 142 |
| Prepaid expenses and other current assets | -624 |
| Accounts payable and accrued expenses | 147 |
| Deferred income | -1,400 |
| Accrued personnel expenses | 2,011 |
| Other noncurrent liabilities | 331 |
| Net cash used in operating activities | -82,484 |
| Additions to property and equipment | 12,749 |
| Proceeds from the sale of property and equipment | 0 |
| Additions to other assets | 135 |
| Maturities of available-for-sale securities | 173,950 |
| Purchases of available-for-sale securities | 119,838 |
| Proceeds from maturity of held-to-maturity investments | 0 |
| Purchases of held-to-maturity investments | 0 |
| Net cash provided by (used in) investing activities | 41,228 |
| Repayment of notes payable | 52 |
| Proceeds from sales of common stock, pursuant to exercise of warrants, net | 0 |
| Proceeds from sales of common stock, pursuant to exercise of options | 371 |
| Proceeds from the sales of common stock and pre-funded warrants, net | 0 |
| Proceeds from the issuance of common stock pursuant to the atm, net | 9,986 |
| Net cash provided by financing activities | 10,305 |
| Net (decrease) increase in cash and cash equivalents | -30,951 |
| Cash and cash equivalents at beginning of period | 61,580 |
| Cash and cash equivalents at end of period | 30,629 |
Perspective Therapeutics, Inc. (CATX)
Perspective Therapeutics, Inc. (CATX)